Nutcracker: RNA design, delivery and manufacturing under one roof
Leveraging an Arch-led $167 million series C round, Nutcracker’s RNA-based therapy for HPV-driven cancers is heading to the clinic
Nutcracker is developing an RNA platform it hopes will solve three challenges with the therapeutic modality: sequence design, delivery and manufacturing.
Nutcracker Therapeutics Inc. launched in 2017 to efficiently create RNA. But CBO Geoff Nosrati told BioCentury it learned that “you need to do so much more than just solve the manufacturing” to be an RNA company, including optimizing sequence design and delivery chemistry. ...